Literature DB >> 12488789

Small fiber dysfunction predominates in Fabry neuropathy.

M Dütsch1, H Marthol, B Stemper, M Brys, T Haendl, M J Hilz.   

Abstract

Fabry disease is an X-linked recessive disease with a reduction of lysosomal alpha galactosidase A and consecutive storage of glycolipids e.g., in the brain, kidney, skin, and nerve fibers. Cardinal neurologic findings are hypohidrosis, painful episodes, and peripheral neuropathy. So far, the neurophysiological findings regarding the extent of large and small fiber dysfunction are contradictory. This study evaluated large and small nerve fiber function in a homogeneous group of Fabry patients. In 24 of 30 Fabry patients with creatinine below 194.7 mmol/L the authors assessed median, ulnar, and peroneal motor conduction velocity (MCV) and median, ulnar, and sural sensory conduction velocity (SCV) nerve conduction to study the function of thickly myelinated nerve fibers. In addition, the authors studied sympathetic skin responses (SSR) at both hands and feet in 24 patients. To evaluate A beta nerve fiber function, the authors determined vibratory detection thresholds (VDT) at the first toe in 30 patients. Function of A delta and C fibers was assessed by quantitative sensory testing of cold detection threshold (CDT) and heat-pain detection thresholds (HPDT). Nerve conduction studies showed significantly decreased amplitudes of MCVs and SCVs in Fabry patients as compared to controls. However, individual results of MCV and SCV studies were only mildly impaired. SSRs were present in all tested patients but SSR amplitudes were significantly decreased in Fabry patients in comparison to controls. VDT, CDT, and HPDT were significantly elevated in Fabry patients as compared to controls. However, only six patients had pathologic VDT, 19 had increased CDT, and 25 had elevated HPDT at a high level of stimulation. In Fabry patients, small fiber dysfunction is more prominent than large fiber dysfunction, confirming previous findings of sural nerve biopsies. The results suggest a higher vulnerability of small-diameter nerve fibers than of the thickly myelinated fibers.

Entities:  

Mesh:

Year:  2002        PMID: 12488789     DOI: 10.1097/00004691-200212000-00011

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.177


  39 in total

Review 1.  Fabry disease: a rare cause of neuropathic pain.

Authors:  Marieke Biegstraaten; Gabor E Linthorst; Ivo N van Schaik; Carla E M Hollak
Journal:  Curr Pain Headache Rep       Date:  2013-10

2.  Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease.

Authors:  L B Jardim; I Gomes; C B O Netto; D B Nora; U S Matte; F Pereira; M G Burin; L Kalakun; R Giugliani; J Becker
Journal:  J Inherit Metab Dis       Date:  2006-07-27       Impact factor: 4.982

3.  [Stimulation of tiny skin areas for selective stimulation of C fibres].

Authors:  T Weiss; W H R Miltner
Journal:  Schmerz       Date:  2006-06       Impact factor: 1.107

4.  GABA-B1 Receptor-Null Schwann Cells Exhibit Compromised In Vitro Myelination.

Authors:  Alessandro Faroni; Simona Melfi; Luca Franco Castelnovo; Veronica Bonalume; Deborah Colleoni; Paolo Magni; Marcos J Araúzo-Bravo; Rolland Reinbold; Valerio Magnaghi
Journal:  Mol Neurobiol       Date:  2018-06-12       Impact factor: 5.590

Review 5.  The clinical approach to autonomic failure in neurological disorders.

Authors:  Eduardo E Benarroch
Journal:  Nat Rev Neurol       Date:  2014-05-27       Impact factor: 42.937

6.  Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Authors:  B Hoffmann; A Garcia de Lorenzo; A Mehta; M Beck; U Widmer; R Ricci
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

Review 7.  [Pain therapy for Fabry's disease].

Authors:  C Sommer; N Uçeyler; T Duning; K Arning; R Baron; E Brand; S Canaan-Kühl; M Hilz; D Naleschinski; C Wanner; F Weidemann
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

8.  Early cardiovascular remodelling in Fabry disease.

Authors:  Luca Costanzo; Sergio Buccheri; Piera Capranzano; Luigi Di Pino; Giuseppina Curatolo; Margherita Rodolico; Stefano Leggio; Anita Blundo; Corrado Tamburino; Ines Monte
Journal:  J Inherit Metab Dis       Date:  2013-04-25       Impact factor: 4.982

9.  Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

Authors:  John Marshall; Karen M Ashe; Dinesh Bangari; KerryAnne McEachern; Wei-Lien Chuang; Joshua Pacheco; Diane P Copeland; Robert J Desnick; James A Shayman; Ronald K Scheule; Seng H Cheng
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

Review 10.  Fabry disease-often seen, rarely diagnosed.

Authors:  Björn Hoffmann; Ertan Mayatepek
Journal:  Dtsch Arztebl Int       Date:  2009-06-26       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.